| BCBS Federal Medical & Drug | 2.04.108 Noninvasive Fetal RHD Genotyping Using Cell-Free Fetal DNA | 2025-12-01 |
| BCBS Federal Medical & Drug | 2.04.115 Comprehensive Genomic Profiling for Selecting Targeted Cancer Therapies | 2025-12-01 |
| BCBS Federal Medical & Drug | 2.04.116 Invasive Prenatal (Fetal) Diagnostic Testing | 2025-12-01 |
| BCBS Federal Medical & Drug | 2.04.117 Genetic Testing for Mitochondrial Disorders | 2025-12-01 |
| BCBS Federal Medical & Drug | 2.04.122 Chromosomal Microarray Testing for the Evaluation of Pregnancy Loss | 2025-12-01 |
| BCBS Federal Medical & Drug | 2.04.126 Germline Genetic Testing for Gene Variants Associated With Breast Cancer in Individuals at High Breast Cancer Risk (CHEK2, ATM, and BARD1) | 2025-12-01 |
| BCBS Federal Medical & Drug | 2.04.139 Genetic Testing for Heterozygous Familial Hypercholesterolemia | 2025-12-01 |
| BCBS Federal Medical & Drug | 2.04.149 Molecular Testing for Germline Variants Associated with Ovarian Cancer (BRIP1, RAD51C, RAD51D, NBN) | 2025-12-01 |
| BCBS Federal Medical & Drug | 2.04.153 Tumor Informed Circulating Tumor DNA Testing for Cancer Management | 2025-12-01 |
| BCBS Federal Medical & Drug | 2.04.154 Germline Genetic Testing for Hereditary Diffuse Gastric Cancer (CDH1, CTNNA1) | 2025-12-01 |